Gossamer Bio, Inc. Common Stock
GOSSGossamer Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies primarily for rare, serious, and underserved diseases. The company's pipeline includes innovative treatments in areas such as immunology, inflammation, and oncology, aiming to address unmet medical needs through novel scientific approaches.
Company News
The Schall Law Firm is seeking investors who purchased Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding its Phase 3 PROSERA study design, specifically concealing adverse facts about...
A securities class action lawsuit has been filed against Gossamer Bio (GOSS) alleging executives concealed placebo response risks in the Phase 3 PROSERA trial for seralutinib. The trial failed to meet its primary endpoint on February 23, 2026, causing an 80% stock price decline. The complaint claims management misled investors about trial design ...
Rosen Law Firm has issued deadline notices for securities class action lawsuits against Gossamer Bio, Upstart Holdings, and POET Technologies. Investors with losses exceeding $100K are encouraged to secure counsel before upcoming deadlines. The lawsuits allege false and misleading statements regarding clinical trial design and other material facts.
Gossamer Bio (GOSS) faces a securities class action lawsuit after its Phase 3 PROSERA trial for seralutinib failed to meet its primary endpoint, causing an 80% stock price drop. The lawsuit alleges the company misled investors about trial design and patient recruitment, particularly regarding heavily-treated patients in Latin America sites showin...
A class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) for allegedly providing materially false and misleading statements regarding its Phase 3 PROSERA study for pulmonary arterial hypertension treatment. The company is accused of expressing confidence in the trial design while concealing adverse facts about placebo respo...
